
|Articles|July 1, 2007
- Volume 0 0
DRUG SPENDING INCREASES DRAMATICALLY IN 8 YEARS
Advertisement
The latest findings from the Agency for Healthcare Research and Quality's News and Numbers report found that spending for medications prescribed in outpatient settings rose from $72 billion in 1997 to $191 billion in 2004. The analysis also showed:
- During the period 1997-2004, the average annual expenditure for Rx drugs for individuals aged 65 and older increased 130% - rising from $819 in 1997 to $1914 in 2004. The average out-of-pocket cost more than doubled for this group, increasing from $483 in 1997 to $1027 in 2004.
- From 1997 to 2004, total purchases of outpatient Rx medicines increased from approximately 2 billion to nearly 3 billion scripts. This increase in part was due to a rise in the average number of prescription drug purchases per year by individuals aged 65 and older, which jumped from 22 to 31 purchases per year.
- During that same period, younger individuals also bought more prescription drugs on average. Individuals under 65 years who purchased prescription medications had purchased 9 Rxs a year on average. In 2004, this figure rose to 13 prescriptions per year.
Articles in this issue
over 18 years ago
pharmacy TECHNOLOGY newsover 18 years ago
pharmacy TECHNOLOGY productsover 18 years ago
health-systems PRODUCT newsover 18 years ago
generic times product newsover 18 years ago
can you READ these Rxs?over 18 years ago
A closer look at new FDA actionsover 18 years ago
can you READ these Rxs?over 18 years ago
compounding HOTLINEover 18 years ago
Is There Science in Quality?over 18 years ago
Vaccines: Are You Protected?Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
COVID-19 Reinfection Heightens Risk of Postacute Sequelae of SARS-CoV-2 in Pediatrics
3
Doxecitine–Doxribtimine Becomes First Approved Treatment for Rare Genetic Disorder
4
From Type 1 to Type 2 and Beyond: Navigating the Landscape of Diabetes
5














































































































































































































